Sector News

Roquette to acquire Qualicaps

July 30, 2023
Life sciences

French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.

The transaction is expected to close in the fourth quarter of 2023 but remains subject to the fulfillment of some customary and legal conditions. Financial details were not disclosed.

Qualicaps, part of Mitsubishi Chemical, is headquartered in Nara, Japan, and is the third largest producer of hard capsules for oral dosage solutions. The company has 1,400 employees located in sites in Asia, Europe and the Americas, and its client base includes major pharmaceutical and food companies around the world.

Roquette commented that this strategic investment offers the ability to expand the global footprint of its pharmaceutical business, as well as enrich its offerings of oral dosage solutions.

The newly combined businesses will offer the most diverse range of oral dosage solutions to existing and new customers, said Roquette.

Pierre Courduroux, CEO of Roquette, said: “Today’s announcement is a significant step in Roquette’s journey to reinforce its position as a key player in Health and Nutrition markets. Qualicaps’ strong position in hard capsules will represent a significant addition to our excipients’ portfolio and will enable our company to offer more solutions responding to the needs of our customers and to the demands of patients who are looking for continuously better treatments.”


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach